Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof

1. A compound of formula (I):

wherein

R1 represents a (C1-C4)alkyl group,

R2 represents —(CH 2 ) n —B wherein n′=0, 1, 2, 3, or 4, and B is a (C3-C5)-cycloalkyl group or a (C1-C4)alkyl group optionally substituted with one or more fluorine atoms or a (C1-C4)alkoxy group,

U represents a carbonyl group or a —CH 2 — group,

Y, Z, V and W represent, independently of each other, a —CH— group, a carbon atom optionally substituted with a group R7, heteroatom selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, or no atom, wherein the ring comprising Y, Z, V, and W is aromatic and 5- or 6-membered,

R3 and R4 represent, independently of each other, a hydrogen atom or a linear (C1-C4)alkyl group, or R3 and R4 form, together with the carbon to which they are attached, a (C3-C5)cycloalkyl group,

m is an integer equal to 1, 2, 3, or 4,

R5 represents a hydrogen atom or a (C1-C4)alkyl group,

R6 represents —(CH 2 ) n -L wherein n=0, 1, 2, or 3, and L is a group independently selected from the group consisting of:

a (C1-C5)alkyl group optionally substituted with a (C1-C4)alkoxy group,

a (C3-C5)cycloalkyl group,

a phenyl group optionally substituted with one or more halogen atoms,

a 5- or 6-membered heteroaryl containing at least one heteroatom selected from the group consisting of a nitrogen atom and a sulfur atom, optionally substituted with a (C1-C4)alkyl group, and

a saturated heterocycle, wherein the said heterocycle is 4- to 7-membered containing at least one heteroatom selected from the group consisting of a nitrogen atom and an oxygen atom, and is optionally substituted in any position, including on the nitrogen atom, with one or more substituents selected from the group consisting of a fluorine atom, a (C1-C4)fluoroalkyl group, a linear or branched (C1-C4)alkyl group, a (C3-C5)cycloalkyl group and a (C1-C4)alkylsulfonamide group, the absolute configuration of a carbon substituted on the said heterocycle possibly being R or S, or racemic, and

R7 represents a hydrogen atom, a (C1-C4)alkyl group or a halogen atom,

in the form of a base or an acid-addition salt thereof, or in the form of an enantiomer or diastereoisomer thereof.

2. The compound according to claim 1 , wherein

R1 represents a (C1-C4)alkyl group,

R2 represents —(CH 2 ) n —B wherein n′=0 or 1, and B is a (C3-C5)cycloalkyl group or a (C1-C4)alkyl group optionally substituted with one or more fluorine atoms or a (C1-C4)alkoxy group,

U represents a carbonyl group or a —CH 2 — group,

Y, Z, V and W represent, independently of each other, a —CH— group, a carbon atom optionally substituted with a group R7, a heteroatom selected from the group consisting of a nitrogen atom and a sulfur atom, or no atom, wherein the ring comprising Y, Z, V, and W is aromatic and 5- or 6-membered, and

R6 represents —(CH 2 ) n -L wherein n=0, 1, 2, or 3, and L is a group independently selected from the group consisting of:

a (C1-C5)alkyl group optionally substituted with a (C1-C4)alkoxy group,

(C3-C5)cycloalkyl group,

an aryl comprising 6 carbon atoms and optionally substituted with one or more halogen atoms,

a 5- or 6-membered heteroaryl containing at least one heteroatom selected from the group consisting of a nitrogen atom and a sulfur atom, optionally substituted with a (C1-C4)alkyl group, and

a saturated heterocycle, wherein the heterocycle is 5- to 7-membered containing at least one heteroatom selected from the group consisting of a nitrogen atom and an oxygen atom, and is optionally substituted in any position, including on the nitrogen atom, with one or more substituents selected from the group consisting of a fluorine atom, a (C1-C4)fluoroalkyl group, a linear or branched (C1-C4)alkyl group, a (C3-C5)cycloalkyl group and a (C1-C4)alkylsulfonamide group, the absolute configuration of a carbon substituted on the said heterocycle possibly being R or S, or racemic.

3. The compound according to claim 1 , wherein U represents a carbonyl group.

4. The compound according to claim 1 , wherein the ring comprising Y, Z, V and W is chosen from phenyl, pyridine, thiazole and thiophene groups.

5. The compound according to claim 1 , wherein R3, R4 and R5 each represents a hydrogen atom.

6. The compound according to claim 1 , wherein the chain —[C(R3R4)] m -U—N(R5)(R6) is in the para or meta position relative to the ring to which it is attached.

7. The compound according to claim 1 , selected from the group consisting of:

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(phenylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl](methyl)amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrid-3-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrid-2-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-(4-{2-[(2-chlorophenyl)amino]-2-oxoethyl}phenyl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-(4-{2-[(3,5-difluorophenyl)amino]-2-oxoethyl}phenyl)-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[(pyrid-4-ylmethyl)amino]ethyl}-phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[(pyrid-2-ylmethyl)amino]ethyl}-phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-(4-{2-[(2-methoxyethyl)amino]-2-oxoethyl}phenyl)-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-{4-[2-(cyclopropylamino)-2-oxoethyl]phenyl}-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-(4-{2-[(1-methylethyl)amino]-2-oxoethyl}phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-{4-[2-(cyclopentylamino)-2-oxoethyl]phenyl}-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrazin-2-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2R)-1-ethylpyrrolidin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2S)-1-ethylpyrrolidin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrid-4-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-(4-{2-[(2-morpholin-4-ylethyl)amino]-2-oxoethyl}phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrid-2-ylamino)ethyl]pyrid-2-yl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-{4-[1-methyl-2-oxo-2-(pyrid-2-ylamino)ethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{6-[2-oxo-2-(pyrid-2-ylamino)ethyl]pyrid-3-yl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(4-ethylmorpholin-3-yl)methyl]amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[6-(2-{[(4-ethylmorpholin-3-yl)methyl]amino}-2-oxoethyl)pyrid-3-yl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2S)-1-ethyl-4,4-difluoropyrrolidin-2-yl]methyl}amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(4-ethylmorpholin-3-yl)methyl]amino}-methyl-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2S,4R)-1-ethyl-4-fluoropyrrolidin-2-yl]methyl}amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2R)-1-(2-fluoroethyl)pyrrolidin-2-yl]methyl}amino)-2-oxoethyl]phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-{4-[2-({[(2R)-1-(methylsulfonyl)pyrrolidin-2-yl]methyl}-amino)-2-oxoethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{5-[2-({[(2R)-1-(2-fluoroethyl)pyrrolidin-2-yl]methyl}amino)-2-oxoethyl]pyrid-2-yl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-({[(2R)-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methyl}amino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-{4-[2-({[(2R)-1-(2,2-difluoroethyl)pyrrolidin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-{4-[2-({[4-(1-methylethyl)morpholin-3-yl]methyl}amino)-2-oxoethyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[4-(2-{[(4-cyclopropylmorpholin-3-yl)methyl]amino}-2-oxoethyl)phenyl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-{5-[2-({[(2R)-1-(2,2-difluoroethyl)pyrrolidin-2-yl]methyl}amino)-2-oxoethyl]pyrid-2-yl}-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-[4-(2-{[(1-methyl-1H-imidazol-5-yl)methyl]amino}-2-oxoethyl)phenyl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[(2-pyrid-3-ylethyl)amino]ethyl}-phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-(4-{2-[(3-morpholin-4-ylpropyl)amino]-2-oxoethyl}-phenyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[(2-pyrid-2-ylethyl)amino]ethyl}-phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[(2-phenylethyl)amino]ethyl}phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-(4-{2-oxo-2-[3-phenylpropyl)amino]ethyl}phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-7-[4-(2-{[2-(1-methyl-1H-pyrrol-2-yl)ethyl]amino}-2-oxoethyl)phenyl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)-1,3-thiazol-2-yl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-(3-methoxypropyl)-N-methyl-4-oxo-7-{4-[2-oxo-2-(pyrid-2-ylamino)ethyl]-phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[4-(2-{[1-(2,2-difluoroethyl)pyrrolidin-3-yl]amino}-2-oxoethyl)phenyl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(3-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-3-oxopropyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(4-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-4-oxobutyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-4-oxo-N-propyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-cyclopentyl-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(5-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-5-oxopentyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

1-ethyl-7-[5-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)thiophen-2-yl]-N,2-dimethyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-{4-[2-({[(2R)-1-ethyl pyrrolidin-2-yl]methyl}amino)-2-oxoethyl]phenyl}-N-methyl-1-(2-methylpropyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[1-({[(2R)-1-ethylpyrrolidin-2-yl]methyl}carbamoyl)cyclopropyl]-phenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{2-[2-({[(2R)-1-ethylpyrrolidin-2-yl]methyl}amino)-2-oxoethyl]-1,3-thiazol-4-yl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-{4-[2-({[(2R)-1-ethylpyrrolidin-2-yl]methyl}amino)-2-oxoethyl]-2-fluorophenyl}-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[3-chloro-4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[3-fluoro-4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-7-[3-methyl-4-(2-{[1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-1-ethyl-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-(cyclopropylmethyl)-7-[4-(2-{[(1-ethylpyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-7-[4-(2-{[(1-ethyl pyrrolidin-2-yl)methyl]amino}-2-oxoethyl)-2-methylphenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide;

2-amino-1-ethyl-7-[3-(2-{[(1-ethyl pyrrolidin-2-yl)methyl]amino}-2-oxoethyl)phenyl]-N-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxamide,

2-amino-1-ethyl-N-methyl-4-oxo-7-{3-[2-oxo-2-(pyrid-2-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide, and

2-amino-1-ethyl-N-methyl-4-oxo-7-{4-[2-(pyrid-2-ylamino)ethyl]phenyl}-1,4-dihydro-1,8-naphthyridine-3-carboxamide.

8. A process for preparing the compound according to claim 1 , comprising the step of reacting a compound of formula (XI):

with a compound of formula HNR5R6, in the presence of a coupling agent and a base, wherein R1, R2, R3, R4, R5, R6, V, W, Y, Z and m are as defined in claim 1 .

9. A process for preparing the compound according to claim 1 , comprising the step of reacting a compound of formula (VII):

with a compound of formula (IXa)

wherein X represents a halogen atom,

G represents a (C1-C4)alkoxy group or a group —NR5R6, and

R1, R2, R3, R4, R5, R6, V, W, Y, Z and m are as defined in, claim 1 .

10. A process for preparing the compound according to claim 1 , comprising reacting a compound of formula (VII):

with a compound of formula (IXb):

wherein G represents a (C1-C4)alkoxy group or a group —NR5R6, X represents a halogen atom and R1, R2, R3, R4, R5, R6, V, W, Y, Z and m are as defined in claim 1 .

11. A pharmaceutical composition, comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

12. A method for treating a leukaemia, comprising administering to a patient in need thereof an effective dose of the compound according to claim 1 .

13. A composition comprising at least one compound according to claim 1 and at least one chemotherapy agent.